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Abstract
Background: The implementation of strategies to monitor and enhance treatment fidelity is of paramount
importance in trials of complex interventions. A recent framework published by the National Institutes of Health
Behavior Change Consortium recommends addressing five areas of treatment fidelity, one of which is delivery of
treatment. This study aimed to explore fidelity to treatment delivery of the ICONS intervention (a systematic voiding
programme [SVP]). This included exploring the feasibility of a method to assess fidelity to treatment delivery and
collecting preliminary evidence of the level of fidelity to SVP delivery in order to inform strategies for improving
fidelity in a future trial.
Methods: Delivery of treatment was recorded by nurses through completion of daily clinical logs, which included:
a voiding interval, proposed voiding times and actual voiding times. The a priori method for assessment of fidelity –
comparing actual voiding times with proposed voiding times – was trialled on a small amount of data. Due to
errors in documentation of the voiding intervals and proposed voiding times it was not possible to assess fidelity
directly as planned. A new method was devised, which included identification of ‘key quality indicators’.
Results: This new approach to assessing fidelity used key quality indicators based upon presence of the data
needed to make the comparison between proposed and actual voiding times. The proportion of clinical logs with
correct documentation of voiding intervals and proposed voiding times was less than 40 %. For clinical logs with
correct documentation, an actual voiding time within 30 min of the proposed voiding time was identified on
approximately 55 % of occasions.
Conclusions: Lessons learnt from this study have implications for the future ICONS definitive trial and for other
trials of complex interventions. Implementation of a complex intervention may often deviate from what is intended.
While careful consideration should be given to the best method of fidelity assessment, an iterative approach
allowing flexibility to adapt pre-planned methods is recommended within feasibility trials. As fidelity to treatment
delivery in the ICONS feasibility trial appeared to be relatively low, more attention to implementation strategies will
be required in the definitive trial.
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Background
Treatment fidelity is of particular relevance to trials of
complex interventions, because intervention delivery has
the potential to differ substantially across research sites as
well as over time. Treatment fidelity is defined as “…the
methodological strategies used to monitor and enhance
the reliability and validity of behavioral intervention-
s…[and]…the methodological practices used to ensure
that a research study reliably and validly tests a clinical
intervention” [1]. The development of effective strategies
to monitor and enhance treatment fidelity is of paramount
importance in complex intervention trials for multiple
reasons.
Measuring fidelity improves the internal validity of a
study: information on fidelity to the intervention can
help estimate the degree to which trial outcomes are at-
tributable to the intervention itself, rather than to other,
unknown factors [1–7]. Without measuring fidelity, re-
searchers do not know whether non-significant out-
comes reflect a lack of intervention effectiveness or a
lack of intervention fidelity [1–3, 6].
Providing information about fidelity to intervention
delivery can enhance a trial’s reproducibility and there-
fore increase its external validity [1, 2, 4, 7–9], as well as
aiding successful dissemination and implementation of
the intervention within clinical practice [1, 5, 6, 10].
Additionally, if fidelity is optimised and therefore vari-
ability in intervention delivery is minimised, then the
statistical power of a study can be increased [1–3]. Fidel-
ity monitoring also provides an understanding of “how
and why an intervention works” [5], including whether
certain ‘doses’ of an intervention are required for a posi-
tive outcome [2].
In 2004 the National Institutes of Health (NIH) Behav-
ior Change Consortium (BCC) published recommenda-
tions on the implementation of treatment fidelity practices
within health behaviour intervention research [1]. These
recommendations include five areas of treatment fidelity:
study design, provider training, treatment delivery, treat-
ment receipt, and enactment of treatment skills [1]. Since
the publication of these treatment fidelity recommenda-
tions, a number of studies of complex interventions have
used the recommendations as a framework against which
to address treatment fidelity [2, 3, 11–14], and the recom-
mendations have been found to be a useful model [3].
There are various challenges to monitoring and enhan-
cing treatment fidelity in complex intervention trials.
Challenges may include constraints on the time, money
and resources required in order to implement strategies
for monitoring fidelity; variation in practice between dif-
ferent professionals delivering the intervention, and the
characteristics of the local setting/population [3, 13, 15].
There may also be a conflict between the desire of re-
searchers for strict compliance with the intervention
protocol and the desire of intervention providers to adapt
the intervention according to the local setting [15].
In this paper we describe how fidelity to ‘treatment deliv-
ery’, one of the five areas of the BCC framework [1], was
assessed in the ‘Identifying Continence OptioNs after
Stroke’ (ICONS) trial [16, 17]. This included exploring the
feasibility of a method to assess fidelity and collecting pre-
liminary evidence of the level of fidelity in order to inform
strategies for improving fidelity in a future trial. We illus-
trate some of the challenges encountered in assessing fidel-
ity to treatment delivery using the example of conservative
interventions for urinary incontinence.
ICONS is a cluster randomised controlled feasibility
trial designed to provide preliminary evidence of the ef-
fectiveness and cost-effectiveness of a systematic voiding
programme (SVP) for the management of continence
after stroke. Urinary incontinence (UI) is a common
problem for patients following a stroke, affecting around
half of patients in the acute phase [18–20]. Conservative
interventions (such as bladder training and pelvic floor
exercises) are recommended as the first-line manage-
ment option for UI post-stroke [21]. The SVP specifies
an algorithm-driven choice of conservative continence
management strategies tailored to the type of urinary
problem and the cognitive ability of the patient. Strat-
egies include bladder training and prompted voiding.
Twelve stroke services in England and Wales were
randomised to receive Usual Care (UC, n = 4), the SVP
(‘Intervention’ sites, n = 4), or the SVP plus Supported Im-
plementation (‘Supported Implementation’ sites, n = 4):
consequently, eight sites in total delivered the SVP. The
Intervention sites included a total of 164 patients and the
Supported Implementation sites included a total of 125
patients. The Supported Implementation arm used facili-
tation, an implementation strategy involving supporting
and enabling people to change their practice [22], to en-
hance embedding of the SVP.
Aim
To explore fidelity to treatment delivery in the ICONS
trial.
Objectives
1. To explore the feasibility of a method to assess
fidelity to treatment delivery.
2. To collect preliminary evidence of the level of
fidelity to treatment delivery.
3. To identify strategies to enhance fidelity in a future
trial.
Methods
Within the ICONS trial there was a process evaluation,
which included assessment of fidelity through an
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examination of: a) completion of intervention documen-
tation (three day diaries and daily clinical logs for partic-
ipants on bladder training and prompted voiding) and b)
adherence to the protocol in terms of allocation of par-
ticipants to the appropriate regime and the management
of catheterisation.
This paper focuses on one aspect of fidelity – daily
clinical logs. Other aspects of fidelity were also explored
in the trial, and these findings are published in the full
trial report [17]. However, this paper focuses on clinical
logs because these constitute the SVP itself, which was
felt to be the ‘core component’ [23] of the intervention.
The clinical logs were used by healthcare staff, predom-
inantly nursing staff (registered) and healthcare assis-
tants (non-registered), to undertake and record delivery
of the SVP each day. One clinical log was completed for
each patient for each day that they received the SVP.
There were two types of clinical logs corresponding to
the two SVP regimes, prompted voiding and bladder
training. The patient’s details and an appropriate voiding
interval were recorded on the clinical log at the start of
each day. The ‘voiding interval’ refers to the specified
length of time between each void, e.g. “3-hourly”, and
healthcare staff were asked to select an appropriate void-
ing interval for each patient at the beginning of every
day. Based upon the voiding interval, healthcare staff
were asked to record a schedule of proposed voiding
times for the patient to follow throughout the day (from
7.30 am until 9.30 pm). Subsequently, any healthcare staff
caring for the patient that day, which may have included
the staff member who originally wrote the schedule,
attempted to follow the schedule of proposed voiding
times: the aim being for the patient to void within 30 min
of each proposed voiding time. Thirty minutes’ leeway
was agreed as a balance between expert opinion that void-
ing should occur within 10 min of the proposed voiding
time and the need to be pragmatic and realistic when
working in an acute or rehabilitation setting. After every
void, healthcare staff were asked to document the actual
voiding time and document whether a number of ‘best
practice’ components had been achieved (e.g. giving en-
couragement; asking the patient if they were wet).
Results
Healthcare staff were provided with written information
in the form of an intervention protocol regarding how to
undertake the SVP, and training was provided in the form
of both online training and/or face-to-face training. How-
ever, uptake was sub-optimal. Details of training provision
and uptake are provided in the full ICONS report [17].
In order to assess fidelity to treatment delivery of the
SVP, daily clinical logs were sampled from all eight sites
delivering the SVP. For each site, time periods of 14 days
each were selected by the trial statistician using stratified
sampling. The planned recruitment period for each site
was split into three strata and two time periods of 14 days
each were sampled from within each stratum. Sites which
extended recruitment had an additional stratum added,
with further 2-week periods sampled according to the dur-
ation of extension. This resulted in site samples compris-
ing between six and nine 14-day periods. The sample of
daily clinical logs comprised all logs for all participants on
the SVP during the sampled 14-day periods. All available
logs were then collected, anonymised, and copied.
The trial was approved by Bradford Research Ethics
Committee (Reference number 10/H1302/60), and by
Research and Development departments in the following
Trusts and Health Boards: Betsi Cadwaladr University
Health Board (no reference number); Blackpool, Fylde
and Wyre Hospitals NHS Foundation Trust (RD0563);
Cambridge University Hospitals NHS Foundation Trust
(AO92132); Cardiff and Vale University Health Board
(10/CMC/49); Cwm Taf Health Board (CT/118/10); East
Lancashire Hospitals NHS Trust (2010/030); Lancashire
Teaching Hospitals NHS Foundation Trust (1298);
North Cumbria University Hospitals NHS Trust (124/
10); University Hospitals of Morecambe Bay NHS Trust
(SFRC 471). All participants provided written informed
consent to take part in the study.
Phase I: exploration of data
Procedure (I)
The clinical logs had been designed in line with generally
accepted ‘best practice’ for bladder training and prompted
voiding. Prior to starting the trial, a plan was developed
for their analysis: the intention was to record the propor-
tion of occasions on which the actual voiding time was
within 30 min of the proposed voiding time. An initial ex-
ploratory phase of data input and analysis was undertaken
in order to ascertain whether this method of fidelity as-
sessment was feasible. One researcher (BC) undertook this
exploratory phase of data input, piloting the proposed
method and identifying issues, which were recorded and
discussed by the authors.
Results (I)
Three major issues arose with the planned method of
data analysis:
1. The voiding interval was sometimes either missing
or documented as a range (e.g. “2 – 3 hourly”)
Both of these did not constitute adherence to the
protocol because the interval between voiding
times was either not defined or not consistent.
This meant that it was not possible to interpret
whether or not the schedule of proposed voiding
times was correct and consequently whether or
not it had been followed.
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2. Some proposed voiding times were missing
Missing proposed voiding times prevented the
research team from being able to assess whether
an actual voiding time had occurred within 30 min
of the corresponding proposed voiding time.
3. The intervals between proposed voiding times were
incorrect
Scheduled voiding intervals were sometimes
miscalculated, for example a 3-hour voiding
interval had been proposed yet voiding times were
scheduled for 8 am, 10 am, 12 pm, etc. In these
cases, assessing whether the actual voiding time
had occurred within 30 min of the proposed
voiding time was meaningless because the
proposed voiding time was itself incorrect given
the prescribed voiding interval.
The exploration of data suggested that, although docu-
mentation of an appropriate voiding interval and a correct
schedule of proposed voiding times are prerequisites for
successful undertaking of the SVP, these were often not
done. Consequently, the original plan of assessing fidelity
to treatment delivery through measuring the proportion
of actual voiding times that had taken place within 30 min
of their proposed voiding times was deemed no longer
feasible. A new method was therefore developed, de-
scribed in Phase II, in order to analyse the same fidelity
data.
Phase II: Revised fidelity assessment
Procedure (I)
Through exploring the reasons why the original method
of fidelity assessment was not possible it became evident
that certain ‘prerequisites’ had to be in place in order to
perform the planned analysis. Working backwards, it
was self-evident that a comparison of actual and pro-
posed voiding times needed correctly documented pro-
posed voiding times. In order to have a schedule of
correctly documented proposed voiding times, it was ne-
cessary to have a correctly documented voiding interval.
Having recognized these ‘prerequisites’, we used them to
identify key quality indicators, which we believed would
allow assessment of fidelity to treatment delivery, based
upon completion of the clinical logs. Key quality indica-
tors were assessed in stages, and are shown in Table 1
with their definitions. A filtering system was developed,
whereby data input for an individual clinical log was ter-
minated at one of two stages (Stage 1 or 2) if the key
quality indicator for that stage had not been achieved.
For each clinical log details of how it performed at each
stage were recorded.
For assessment of Stage 3 (the comparison of the actual
voiding times to their corresponding proposed voiding
times), any ‘clinically justifiable’ explanations documented
were noted and adjustments made for them in the ana-
lysis. The main criteria for comments to be deemed ‘clin-
ically justifiable’ were agreed between the authors and are
shown in Additional file 1.
Data input was undertaken by one researcher (BC).
The final analysis of the data was undertaken jointly by
two researchers (BC and ML). A simple descriptive
quantitative analysis was performed, exploring how well
clinical logs from each trial arm had performed accord-
ing to the key quality indicators.
Results (II)
A total of 396 clinical logs were analysed from Interven-
tion sites and 320 from Supported Implementation sites,
covering approximately 25 % of trial participants. The ma-
jority of clinical logs were for the prompted voiding
programme. Results for fidelity to treatment delivery are
shown in Table 2, categorised into Intervention and Sup-
ported Implementation trial arms (four sites in each arm).
The proportion of clinical logs that had both an appro-
priate voiding interval and a correct schedule of pro-
posed voiding times documented was 38.9 % for the
Intervention arm and 31.9 % for the Supported Imple-
mentation arm. This meant that 154 and 102 clinical
logs passed both Stages 1 and 2 in the Intervention and
Supported Implementation arms, respectively.
For clinical logs that passed Stages 1 and 2, the pro-
portion of occasions on which an actual voiding time
was documented that was within 30 min of the corre-
sponding proposed voiding time was 54.8 % for the
Intervention arm and 56.0 % for the Supported Imple-
mentation arm. For these clinical logs, which had passed
Stages 1 and 2, it was documented that two key aspects
of best practice, giving encouragement and asking the
patient if they were wet, were performed on the majority
of occasions.
One principle of the SVP was that the voiding interval
should be individualised and specific to each patient de-
pending, for example, on their pattern of incontinence.
The distribution of voiding interval frequencies for the
clinical logs that passed Stages 1 and 2 (shown in Fig. 1)
suggests that different voiding intervals were used, ra-
ther than a uniform interval being prescribed across all
patients and days. The mean voiding interval was 2.33 h
for the Intervention arm and 2.32 h for the Supported
Implementation arm. The mean number of proposed
voiding times documented each day was 5.08 and 4.98,
respectively.
Discussion
This paper describes the assessment of fidelity to treat-
ment delivery of the ICONS systematic voiding
programme (SVP). Assessment of fidelity to treatment
delivery was based upon data collected from daily
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Table 2 Results for fidelity to treatment delivery in the ICONS trial
Trial arm Interventiona Supported implementation
Number of clinical logs analysed 396 320
Number of patients 40 31
Percentage of total number of patients 24.4 % (40/164) 24.8 % (31/125)
Percentage of clinical logs according to type of regime: Prompted Voiding
(PV)/Bladder Training (BT)
PV: 90.4 % PV: 100.0 %
/BT: 9.6 % /BT: 0.0 %
STAGE 1: % with voiding interval present and correctly documented 83.3 89.4
STAGE 2: % with both voiding interval and schedule of proposed
voiding times present and correctly documented
38.9 31.9
No. of clinical logs that achieved both Stage 1 and Stage 2 154 102
For the clinical logs that achieved both Stage 1 and Stage 2:
STAGE 3: On average, how often was an ‘actual voiding time’ documented
that was within 30 min of the proposed voiding time?b
54.8 % 56.0 %
STAGE 4a: On average, how often was encouragement documented as given? 58.4 % 57.5 %
STAGE 4b: On average, how often was it documented that the patient had been
asked if they were wet?c
57.9 % 65.9 %
aThis refers to sites which delivered the intervention only, and not the supported implementation package
bOccasions on which a clinically justifiable explanation was given for an early/late/missing actual voiding time were exempted from this analysis
cThis applies to Prompted Voiding clinical logs only
Table 1 Key quality indicators used to assess fidelity to treatment delivery as recorded on the clinical logs
Stage Key quality indicator Definitions of components
1. VOIDING INTERVALa: The voiding interval is the specified length of time between each
void for the patient for that day. The voiding interval determines
the frequency of voiding throughout the day.
Is the voiding interval present and appropriately documented? Appropriate documentation refers to the documentation of
an individual number (such as “2-hourly”) and not a range
(such as “2 – 3 hourly”).
2. PROPOSED VOIDING TIMESa: Proposed voiding times should be documented at the start
of each day, based upon the voiding interval. The proposed
voiding times form a schedule of times for toileting, which
healthcare staff should then try to follow.
Are proposed voiding times present and documented correctly? Proposed voiding times ‘present’: There should be no missing entries
between the first and last documented proposed voiding time.
Proposed voiding times ‘documented correctly’: Each interval between
consecutive proposed voiding times should be identical to the
voiding interval (e.g. 2 h between consecutive proposed voiding
times for a voiding interval of “2-hourly”).
3. ACTUAL VOIDING TIMES – within schedule: The actual voiding times are the times at which the patient was
toileted, and are recorded by healthcare staff.
For how many proposed voiding times is the ‘actual
voiding time’ documented and within 30 min?
The ‘gold standard’ for the ICONS intervention is that an actual
voiding time should be within 30 min of a proposed voiding time.
4. (a) GOOD PRACTICE – Encouragement: For how many proposed
voiding times is the answer “YES” documented in response
to the question “Did you give encouragement?”
For each voiding occasion, healthcare staff are required to
indicate on the clinical log whether they have undertaken a
number of ‘best practice’ components of the regime. These
include giving encouragement to the patient and asking them
whether they are wet (if on prompted voiding regime).4. (b) GOOD PRACTICE – Asking the patient if they are wet
b:
For how many proposed voiding times is the answer “YES”
documented in response to the question “Did you ask the
patient if they were wet?”
aA clinical log was not examined further if it did not achieve this stage
bThis criterion refers to prompted voiding clinical logs only
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clinical logs completed by healthcare staff. Significant is-
sues arose when the planned method of data analysis
was trialled on the actual data collected: the voiding
interval was often either missing or incorrectly docu-
mented and the schedule of proposed voiding times was
either incomplete or incorrect. Both the voiding interval
and schedule of proposed voiding times are prerequisites
for undertaking the SVP. Therefore, the clinical logs had
not been completed as intended. This meant that the a
priori planned method for data analysis was unfeasible
because it was often not possible to calculate the differ-
ences between actual and proposed voiding times. A
new method was developed, in which key quality indica-
tors were identified and an assessment made for each
clinical log regarding its performance against each key
quality indicator. This method appeared to work well
and revealed overall a relatively low level of fidelity to
treatment delivery.
The first objective of this study was to explore the
feasibility of a method to assess fidelity to treatment de-
livery in the ICONS trial. The issues highlighted in the
results from Phase I suggest that researchers should not
assume that components of their intervention will ne-
cessarily be delivered in exactly the way they expect. In
this trial, the voiding interval and schedule of proposed
voiding times were not documented as expected. It is
important for researchers to consider for every compo-
nent of a complex intervention ways in which actual
practice may deviate from the protocol, and take steps
to minimise this. Researchers should also ensure that
measurement of fidelity is sufficiently sensitive to cap-
ture meaningful variations to ‘core components’ of the
intervention [23].
BCC recommendations state that interventions should
be assessed against “a priori criteria” [1]. For the ICONS
trial, a priori criteria were set, namely that actual voiding
times should be within 30 min of their proposed voiding
times. However, it was not foreseen that errors would
arise in the documentation of both the voiding interval
and the proposed voiding times, two prerequisites for
both successfully undertaking the SVP and enabling the
calculation of differences between actual and proposed
voiding times. These issues rendered the planned
method of fidelity assessment unfeasible. This demon-
strates that, whilst it is important to develop plans for
the assessment of fidelity to treatment delivery at the
study design stage, it is necessary to remain flexible and
adapt the planned method in light of unforeseen issues.
Fidelity assessment should be an iterative process within
trials [7].
The revised method of assessing fidelity to treatment
delivery through the evaluation of clinical logs according
to key quality indicators provided a feasible alternative.
Despite the complexities of the information, data could
be extracted from all clinical logs and used to assess fi-
delity to treatment delivery. However, this method of
analysis has some drawbacks.
Clinical logs with a missing or incorrect voiding inter-
val or an incomplete or incorrect schedule of proposed
voiding times were not examined further. There were
some clinical logs that contained only a small number of
errors, for example just one or two incorrect proposed
voiding times, but that otherwise demonstrated reason-
ably high levels of fidelity to treatment delivery, for ex-
ample, by including a number of actual voiding times
documented as within 30 min of their proposed voiding
times. However, these data were not captured and conse-
quently not included in the analysis. In a future trial, it
would be useful to consider whether this method of data
input could be amended to account for varying degrees
of fidelity, rather than simply accepting or rejecting clin-
ical logs at earlier stages of the process.
In this trial, documentation of delivery of the SVP was
used as a proxy measure for fidelity to actual treatment
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Fig. 1 Bar chart to depict voiding intervals used by healthcare staff. The data in this Figure relate to clinical logs that achieved Stages 1 and 2 only
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delivery. Findings from other components of the process
evaluation, for example interview data, suggest that
healthcare staff did not always document everything that
they did [17], and therefore it is likely that a method of fi-
delity assessment based upon healthcare staff recording of
activity underestimates the true level of fidelity to treat-
ment delivery. Similarly, it also appeared that at times
healthcare staff found the amount of paperwork associated
with the intervention onerous [17]; it is therefore worth
considering whether the clinical logs could be simplified
while still providing a structure for SVP delivery.
Some aspects of the clinical logs, such as documenting
whether encouragement had been given, involved more
subjective self-reporting by healthcare staff. There is
therefore a risk of self-report bias in the use of clinical logs
to measure fidelity, as self-report measures can often be
inaccurate and may over-estimate fidelity [24–26]. Add-
itionally, there is evidence from the clinical logs that se-
lective documentation was sometimes undertaken, in
which data were more likely to be missing if the required
intervention component had not been achieved. For ex-
ample, it appeared that sometimes healthcare staff would
leave the answer to a question such as “Was encourage-
ment given?” as missing rather than document “no”. In
the future trial a more objective measure of fidelity may
be appropriate, for example direct observation. However,
this could affect intervention delivery as a consequence of
providers being observed [26] and may not be feasible due
to ethical issues inherent in observing patients receiving
personal care.
A key limitation of the assessment of fidelity to treat-
ment delivery in this trial was that data were not avail-
able regarding the total number of clinical logs per trial
arm that should have been completed. It was not pos-
sible to calculate these numbers due to the complexities
inherent in the delivery of the SVP. For example, some-
times patients would start and stop the SVP at various
time points during their stay due to needing a catheter
for a short period, or due to becoming temporarily med-
ically unstable, and the dates for these variations were
not consistently recorded. This meant that it was not
possible to reliably calculate the theoretical numbers of
clinical logs that should have been received. The first
step in fidelity to delivery of the SVP was the completion
of a clinical log and therefore a comparison of the num-
bers of clinical logs expected and received could add an-
other stage to the assessment of fidelity to treatment
delivery. In a future trial it will be important to develop
a process that will ensure it is possible to calculate the
number of clinical logs that should have been completed
per sampling period, per trial arm.
A second objective of this study was to obtain prelim-
inary evidence of fidelity to treatment delivery within the
ICONS trial. Documentation of an appropriate voiding
interval and a correct schedule of proposed voiding
times (Stages 1 and 2) was often not done correctly. The
original intention was to determine whether a patient had
voided within 30 min of the proposed voiding time, but
when this method proved unfeasible it was necessary to
reconsider what constituted a reasonably valid method to
assess ‘fidelity’. It was decided that the documentation of
an appropriate voiding interval and a correct schedule of
proposed voiding times were the first steps in the success-
ful undertaking of the SVP and should therefore be the
first steps in the assessment of fidelity to treatment deliv-
ery. The clinical logs that did not contain both these com-
ponents (61.1 % in the Intervention sites; 68.1 % in the
Supported Implementation sites) therefore lacked the ne-
cessary information for healthcare staff to be able to fol-
low the SVP throughout the day and this constitutes a
lack of fidelity. It is unclear why this happened, but one
possible explanation is that healthcare staff misunderstood
the principles of the SVP. In the future trial this needs to
be addressed through detailed consideration of methods
of implementation of the SVP, for example giving
healthcare staff time to become familiar with and prac-
tice using the SVP before the trial intervention period
begins [23, 27]. The future definitive ICONS trial will
include a detailed plan for improved training provision,
uptake and monitoring.
Whilst a key principle of the ICONS SVP is that void-
ing should occur within 30 min of a proposed voiding
time, other aspects of treatment delivery were also im-
portant: healthcare staff should have given sufficient
consideration to the most appropriate voiding interval
for a particular patient on a particular day, and should
also have attempted to undertake the SVP throughout
the day, from 7.30 am until 9.30 pm. These components
were only examined for clinical logs that achieved Stages
1 and 2. It was found that the length of the voiding
interval did vary across days and across patients (data
not presented), and this suggests that there was some in-
dividualisation of voiding interval. The mean number of
proposed voiding times per clinical log was also rela-
tively high for each arm, at around five for both arms,
given that the voiding interval was almost always be-
tween 2-hourly and 3-hourly (as shown in Fig. 1) and
that the SVP only ran from 7.30 am until 9.30 pm. This
suggests that, on the whole, the SVP was undertaken
through most of the day. Fidelity to these two compo-
nents of the SVP therefore seems relatively high for clin-
ical logs that passed Stages 1 and 2.
For clinical logs that achieved Stages 1 and 2, the per-
centage of occasions on which the actual voiding time
occurred within 30 min of the proposed voiding time
was around 55 %. A key principle of the SVP is that
voiding occurs at a regular, consistent interval as part of
a progressive voiding schedule [28, 29]; on a substantial
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proportion of occasions ICONS patients did not void at,
or close to, the scheduled time. Fidelity to this principle
of the SVP therefore appeared to be relatively low. One
possible explanation for the relatively low fidelity is that
returning to all patients on the SVP at their individualised
times posed the most challenges to practice and was not
always achievable. Additionally, there is evidence that
staffing levels associated with weekend working can affect
clinical outcomes [30], and it is possible that documenta-
tion of the SVP and fidelity to it could have been affected
by different patterns of working/staffing at weekends ver-
sus in the week. However, exploring such patterns was be-
yond the scope of this paper. When fidelity to the
intervention is low, the degree to which trial outcomes
can be attributed to the intervention is compromised [31].
Fidelity to two ‘best practice’ components of the SVP,
giving the patient encouragement and asking the patient
if they were wet, was relatively high, although data for
these components were extracted only from clinical logs
that achieved Stages 1 and 2. Whilst these results are en-
couraging, they should be interpreted with caution as
healthcare staff simply documented ‘yes’ or ‘no’ in rela-
tion to the two components, and, without asking for fur-
ther detail to be provided about the manner in which
these elements were provided, it is difficult to assess
how accurate these measures are. There is also the risk
of positive bias in self-reporting these more subjective
elements of the programme [25].
A limitation of this study is that the analysis does not
reflect the sampling strategy, which had two levels of
clustering – by time and by patient. In our analysis we
grouped together the clinical logs per site and then per
trial arm and presented pooled results. The data were
merged in this fashion in order to simplify the analysis
and subsequent presentation. This method is unlikely to
have affected our overall conclusions in relation to treat-
ment fidelity, but would have implications if we were to
perform any inferential statistics.
Key lessons have been learnt from the assessment of
fidelity to treatment delivery in the ICONS trial. Real-
life practice may often deviate from the protocol: the
ICONS protocol for the SVP was often not followed and
this highlights how important it is for researchers to
consider how real-life practice may deviate from what
was intended and explore ways in which to minimise
this. An iterative approach to fidelity assessment is im-
portant in trials of complex interventions: ideally, fidelity
data should be examined and analysed whilst the trial is
ongoing, allowing issues to be addressed as the trial pro-
gresses. Different ways of defining and assessing fidelity
should be considered: trials of complex interventions
should consider the relative merits of subjective, self-
reported measures of fidelity versus more objective mea-
sures, such as direct observation, and select the method
most feasible and appropriate for the study. More com-
prehensive implementation strategies will be important
in a future evaluation trial in order to improve fidelity,
given that the overall fidelity to treatment delivery in the
ICONS feasibility trial appeared to be relatively low.
Conclusions
Fidelity to treatment delivery has been explored in detail
in the ICONS feasibility trial. The feasibility of a proposed
method for fidelity assessment has been investigated and
lessons learnt from this experience will guide fidelity as-
sessment in a future evaluation trial and may be of use to
other research teams designing trials of complex interven-
tions. Whilst it is important to agree upon strategies for
implementing and assessing fidelity to treatment delivery
during the design phase, researchers should still be pre-
pared to adapt their planned methods during a trial in line
with evolving issues. The assessment of fidelity should be
an iterative process, with opportunities for fidelity data
gathered to inform ongoing strategies to monitor and im-
prove fidelity to treatment delivery. This exploration of fi-
delity to treatment delivery of the ICONS intervention
(the SVP) has highlighted issues in the implementation of
the SVP that will need to be addressed in a future trial. By
addressing these issues it is possible that we will be able to
improve healthcare staff fidelity to the protocol and poten-
tially allow greater flexibility in delivery of the protocol
amongst healthcare staff whilst not adversely impacting
on the active components of the SVP.
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